In an accompanying commentary, Lance Liotta and Emanuel Petricoin from George Mason University stress that, "the impact of these results on cancer biomarker discovery efforts is significant." They explain that currently, following blood collection, it is standard practice for enzyme inhibitors to be added to the blood to suppress enzymatic breakdown. The report from Tempst et al. now suggests that this suppression may in fact be preventing the generation of biomarkers that hold great promise in the detection of disease - in this case prostate, bladder or breast cancer.
TITLE: Differential exoprotease activities confer tumor-specific serum peptidome patterns
AUTHOR CONTACT:
Paul Tempst
Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Phone: 212-639-8923;
Fax: 212-717-3604;
E-mail: p-tempst@mskcc.org.
View the PDF of this article at: https://www.the-jci.org/article.php?id=26022
ACCOMPANYING COMMENTARY:
TITLE: Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold
AUTHOR CONTACT:
Lance A. Liotta
George Mason University, Manassas, Virginia, USA
Phone: 703-993-9444;
Fax: 703-993-4288;
E-mail
'"/>
Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
4-Jan-2006